Drug Trial Radar · NCT05877547
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
381
Actual
Start
Jun 23, 2023
Primary completion
Dec 29, 2025
Study completion Dec 29, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Conditions
- Non-alcoholic Fatty Liver Disease
- Fatty Liver, Nonalcoholic
- NAFLD
- Nonalcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
Interventions
EfinopegdutideDrug
Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
SemaglutideDrug
SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
PlaceboDrug
SC injection of matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52Time frame: Week 52
- Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to 60 weeks
- Percentage of Participants Discontinuing Study Medication Due to an AETime frame: Up to 52 weeks
Locations
175 sites in 26 countries. Site status is shown where the registry gives one.
The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3
Chandler, Arizona
The Institute for Liver Health II dba Arizona Clinical Trials - Peoria ( Site 3289)
Peoria, Arizona
The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 3218)
Tucson, Arizona
Del Sol Research Management, LLC ( Site 3211)
Tucson, Arizona
Om Research - Apple Valley ( Site 3244)
Apple Valley, California
Om Research LLC ( Site 3245)
Camarillo, California
Velocity Clinical Research, Gardena ( Site 3225)
Gardena, California
Velocity Clinical Research, Huntington Park ( Site 3217)
Huntington Park, California
Velocity Clinical Research, San Diego ( Site 3226)
La Mesa, California
Om Research LLC ( Site 3229)
Lancaster, California
Velocity Clinical Research, Westlake ( Site 3216)
Los Angeles, California
Velocity Clinical Research, Panorama City ( Site 3214)
Panorama City, California
California Liver Research Institute ( Site 3232)
Pasadena, California
Clinical Trials Research ( Site 3230)
Sacramento, California
Excel Medical Clinical Trials ( Site 3246)
Boca Raton, Florida
Synergy Healthcare ( Site 3286)
Bradenton, Florida
Synergy Healthcare LLC ( Site 3290)
Brandon, Florida
Top Medical Research ( Site 3209)
Cutler Bay, Florida
Covenant Metabolic Specialists, LLC ( Site 3231)
Fort Myers, Florida
Velocity Clinical Research, Hallandale Beach ( Site 3241)
Hallandale, Florida
Indago Research & Health Center, Inc ( Site 3207)
Hialeah, Florida
Sweet Hope Research Specialty, Inc-Research ( Site 3200)
Hialeah, Florida
Florida Research Institute ( Site 3243)
Lakewood Rch, Florida
Genoma Research Group ( Site 3242)
Miami, Florida
Floridian Clinical Research, LLC ( Site 3203)
Miami Lakes, Florida
Southeast Clinical Research Center ( Site 3288)
Dalton, Georgia
Eagle Clinical Research ( Site 3233)
Chicago, Illinois
University of Iowa ( Site 3213)
Iowa City, Iowa
Kansas City Research Institute ( Site 3249)
Kansas City, Missouri
The Machuca Foundation ( Site 3234)
Las Vegas, Nevada
Velocity Clinical Research, Syracuse ( Site 3227)
East Syracuse, New York
New York Gastroenterology Associates ( Site 3252)
New York, New York
Velocity Clinical Research, Cincinnati ( Site 3237)
Cincinnati, Ohio
Velocity Clinical Research, Providence ( Site 3222)
East Greenwich, Rhode Island
Velocity Clinical Research, Austin ( Site 3235)
Austin, Texas
South Texas Research Institute - Brownsville ( Site 3285)
Brownsville, Texas
Velocity Clinical Research, Dallas ( Site 3220)
Dallas, Texas
Houston Research Institute ( Site 3262)
Houston, Texas
American Research Corporation ( Site 3202)
San Antonio, Texas
Pinnacle Clinical Research ( Site 3284)
San Antonio, Texas
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.